Sunitinib’s initial clinical development in the early 2000s focused on metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumors (GIST), two tumor types highly dependent on VEGF-, PDGF-, and KIT-mediated pathways [72]. Here, KIT is linked to neoplasm.